Terms: = Kidney tumors AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF
66 results:
1. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract] [Full Text] [Related]
3. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
[TBL] [Abstract] [Full Text] [Related]
4. Recurrent CYP2A6 gene mutation in biphasic hyalinizing psammomatous renal cell carcinoma: Additional support of three cases.
Ding X; Zhang W; Yu W; Li Y; Shao G; Zhang L; Zhao RC; Li X
Pathol Res Pract; 2023 May; 245():154468. PubMed ID: 37104959
[TBL] [Abstract] [Full Text] [Related]
5. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Genomic Profiling of nf2-Mutated kidney tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract] [Full Text] [Related]
7. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity.
Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
[TBL] [Abstract] [Full Text] [Related]
8. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.
Sahu DK; Singh N; Das M; Rawat J; Gupta DK
Pediatr Surg Int; 2022 Nov; 38(11):1601-1617. PubMed ID: 36107237
[TBL] [Abstract] [Full Text] [Related]
9. merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract] [Full Text] [Related]
10. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract] [Full Text] [Related]
11. The emerging role of nf2 alterations in new and established subtypes of renal cell carcinoma.
Paintal A; Antic T
Hum Pathol; 2023 Mar; 133():87-91. PubMed ID: 35705112
[TBL] [Abstract] [Full Text] [Related]
12. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract] [Full Text] [Related]
13. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and molecular characterization of biphasic hyalinizing psammomatous renal cell carcinoma: further support for the newly proposed entity.
Wang XT; Xia QY; Fang R; Zhang RS; Ye SB; Li R; Wang X; Lu ZF; Ma HH; Zhou XJ; He HY; Zhao M; Rao Q
Hum Pathol; 2022 May; 123():102-112. PubMed ID: 35192800
[TBL] [Abstract] [Full Text] [Related]
15. Multiregion sequencing of sarcomatoid renal cell carcinoma arising from autosomal dominant polycystic kidney disease.
Lee E; Guan P; Lim AH; Loh JW; Tan GF; Loh T; Ng DYX; Lee JY; Goh S; Liu W; Ng CC; Teh BT; Chan JY
Mol Genet Genomic Med; 2022 Mar; 10(3):e1853. PubMed ID: 35122417
[TBL] [Abstract] [Full Text] [Related]
16. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
17. nf2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases.
Paintal A; Tjota MY; Wang P; Fitzpatrick C; Wanjari P; Stadler WM; Gallan AJ; Segal J; Antic T
Am J Surg Pathol; 2022 May; 46(5):617-627. PubMed ID: 35034039
[TBL] [Abstract] [Full Text] [Related]
18. Spectrum of biphasic renal cell carcinomas with hyalinized stroma and psammoma bodies associated and not associated with nf2 alteration.
Chumbalkar V; Wang P; Paner GP
Hum Pathol; 2022 Mar; 121():11-18. PubMed ID: 34929230
[TBL] [Abstract] [Full Text] [Related]
19. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway.
Mohanty SK; Satapathy A; Aggarwal A; Mishra SK; Sampat NY; Sharma S; Williamson SR
Mod Pathol; 2022 Mar; 35(3):361-375. PubMed ID: 34802045
[TBL] [Abstract] [Full Text] [Related]
20. Renal cell tumor with sex-cord/gonadoblastoma-like features: analysis of 6 cases.
Wang G; Amin MB; Grossmann P; Ptáková N; Hayes M; Hartmann A; Agaimy A; Lopez JI; Michal M; Hes O
Virchows Arch; 2022 Feb; 480(2):349-358. PubMed ID: 34775513
[TBL] [Abstract] [Full Text] [Related]
[Next]
